Vildaron-M 50/850 Tablet
Vildagliptin 50 mg + Metformin 850 mg
| Composition | Vildagliptin 50 mg + Metformin 850 mg |
|---|---|
| Dosage Form | Tablet |
| Pack Type | Box |
| Pack Size | 10 x 15 (Alu-Alu) |
| MRP | ₹ 2350 |
| Therapy | Cardiac + Diabetic — DPP-4 inhibitor combination |
| Storage | Store below 25°C. |
📱 WhatsApp Enquiry📞 Call: +919041677932
About Vildaron-M 50/850 Tablet
Vildaron-M 50/850 Tablet contains Vildagliptin 50 mg + Metformin 850 mg. Vildagliptin is a selective DPP-4 inhibitor with weight-neutral, low-hypoglycaemia profile.
Indicated for type-2 diabetes mellitus as monotherapy or in combination with Metformin / Pioglitazone.
Camrut Healthcare manufactures the Vildaron range under WHO-GMP conditions for PCD pharma franchise across India.
Indications
- Type-2 diabetes mellitus
- Add-on to metformin or pioglitazone
- Glycaemic intensification
Mechanism of Action
Vildagliptin inhibits DPP-4, prolonging incretin (GLP-1, GIP) action. Increased glucose-dependent insulin secretion and decreased glucagon release improve glycaemic control without producing hypoglycaemia in non-eugenic states. Metformin activates AMPK, reducing hepatic glucose output and improving peripheral insulin sensitivity.
Dosage & Administration
['Adults: take with or without food', 'Adjust dose in renal impairment', 'Monitor liver enzymes periodically', 'Use under physician supervision']
Side Effects
['Nasopharyngitis', 'Headache', 'Hypoglycaemia (with SU/insulin)', 'Hepatic enzyme elevation (rare)', 'GI upset (with metformin component)']
Contraindications & Precautions
['Type-1 diabetes', 'Diabetic ketoacidosis', 'Significant hepatic impairment', 'Pregnancy and breastfeeding']
Storage
Store below 25°C.
Vildaron-M 50/850 Tablet is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →
Frequently Asked Questions
q
a
q
a
q
a
q
a
q
a
Related Products